ANNX

Rating neutralAI MemoPost-earnings T+1

Annexon

As of 2026-08-18/Post-earnings T+1/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-18 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

ARCHER II Phase 3 GA topline data • 2026-11-16

Base target: $7 / p=45% prob

Biggest risk

The thesis remains highly binary. GA efficacy, GBS regulatory acceptance, and ANX1502 proof-of-concept are not yet established, while the prior 10-K identified regulatory generalizability and financing/dilution risks [#10-K-2026-03-30]. No verified post-print analyst revisions or target changes are available.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

The Q2 update increased near-term catalyst density: positive early GBS FORWARD outcomes, a Q4 2026 BLA path, ARCHER II progression with Month 15 and Month 24 endpoints, ANX1502 data, and runway extended into 2028 [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2]. Success in either lead program could materially re-rate the stock.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-18

Base target

p=45%

Bull target

$12

p=25%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Runway support versus dilution overhang
ANX1502 proof-of-concept data
The Q2 update increased near-term catalyst density: positive early GBS FORWARD outcomes, a Q4 2026 BLA path, ARCHER II progression with Month 15 and Month 24 endpoints, ANX1502 data, and runway extended into 2028 [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].

BearKey bullets

Binary failure or delay in ARCHER II Phase 3 geographic-atrophy data.
Clinical execution, enrollment, endpoint interpretation, and longer follow-up remain material risks.
Future equity issuance could dilute holders if development timelines or milestones slip.

WatchKey bullets

ARCHER II Phase 3 GA topline data

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+1

Base case: $7 (p=45%)

Target spread vs base: +70% / -59%

Scenario probabilities

Bull Target: $12 (p=25%)Base Target: $7 (p=45%)Bear Target: $3 (p=30%)

Commentary

This is a T+1 post-earnings follow-up. The primary 8-K and stored earnings transcript support a constructive milestone update and improved runway, but the packet does not provide a verified EPS/consensus surprise, analyst target revisions, or a confirmed immediate post-print price reaction [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2]. Low coverage and binary clinical risk favor monitoring rather than high-conviction positioning.

As of 2026-08-18 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Runway support versus dilution overhang
ANX1502 proof-of-concept data

Scenarios

Bull Target (Scenario probability)

$12 / p=25% prob

Base Target (Scenario probability)

$7 / p=45% prob

Bear Target (Scenario probability)

$3 / p=30% prob

Analysis 2026-08-18 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-16
ARCHER II Phase 3 GA topline data
Vonaprument ARCHER II remains on track for a Q4 2026 Month 15 primary-endpoint readout, with a newly added Month 24 dual-primary strategy intended to strengthen the potential label. The outcome remains binary and is the principal valuation driver [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 45.00% • Move 70.00% • Priced-in 35.00%
EVENT2026-11-16
Tanruprubart GBS regulatory progression
Annexon reports positive early FORWARD outcomes, an EU marketing-authorisation application under review, and a planned U.S. BLA submission in Q4 2026. Regulatory generalizability and submission risk remain material [#SEC-8K-2026-08-12] [#EARNINGS-TRANSCRIPT-2026Q2].
Prob 50.00% • Move 35.00% • Priced-in 30.00%

Short-term Catalysts

Next few weeks

Runway support versus dilution overhang
2026-11-16
The announced $200 million credit facility extends anticipated runway into 2028, but the outstanding equity-issuance capacity disclosed in the 10-K leaves dilution and capital-structure risk active if milestones slip [#SEC-8K-2026-08-12] [#10-K-2026-03-30].
Prob 60% • Move -12% • Priced-in 55%

Long-term Catalysts

Months to a year

ANX1502 proof-of-concept data
2027-08-18
Proof-of-concept data for the first-in-kind oral C1 inhibitor ANX1502 are expected in fall 2026, providing additional pipeline optionality but with earlier-stage and higher uncertainty than the lead programs [#SEC-8K-2026-08-12].
Prob 35% • Move 20% • Priced-in 15%

Risks

Binary failure or delay in ARCHER II Phase 3 geographic-atrophy data.
Clinical execution, enrollment, endpoint interpretation, and longer follow-up remain material risks.
Future equity issuance could dilute holders if development timelines or milestones slip.
Post-earnings EPS or consensus surprise, analyst revisions, and immediate market reaction are not verified in the available evidence.
Regulatory or generalizability issues could delay or weaken the tanruprubart BLA path.

Peers

Symbol	Summary
CLYM	Loose same-sector, similar-market-cap comparator; useful for small-cap biotech volatility and milestone-risk context, not a direct operating peer.
DSGN	Loose same-sector, similar-market-cap comparator; valuation comparison is limited without indication or mechanism matching.
GERN	Development-stage biotechnology comparator in the packet; relevant mainly for readout and financing sensitivity.
JANX	Similar-market-cap biotechnology comparator; useful for pipeline-driven volatility context rather than direct business benchmarking.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-18

Loading AI feed…

Symbol

Summary

CLYM

Loose same-sector, similar-market-cap comparator; useful for small-cap biotech volatility and milestone-risk context, not a direct operating peer.

DSGN

Loose same-sector, similar-market-cap comparator; valuation comparison is limited without indication or mechanism matching.

GERN

Development-stage biotechnology comparator in the packet; relevant mainly for readout and financing sensitivity.

JANX

Similar-market-cap biotechnology comparator; useful for pipeline-driven volatility context rather than direct business benchmarking.